Home

Preprocedural administration of an oral colchicine load does not reduce the risk of myocardial injury or 30-day major adverse cardiovascular events (MACE) in patients undergoing percutaneous coronary intervention (PCI), according to findings from the COLCHICINE-PCI (Effects of acute colchicine administration prior to percutaneous coronary intervention) clinical trial. However, the study concluded that colchicine could prevent vascular inflammation during an acute injury.

Binita Shah (VA New York Harbor Healthcare System and NYU School of Medicine; New York; USA) presented the findings of the trial on behalf of the COLCHICINE-PCI study team at the American Heart Association Scientific Sessions (AHA 2019; 16–18 November, Philadelphia, USA). The investigator-initiated, randomised, double-blinded, placebo-controlled, single-centre trial is the first to evaluate the effects of acute preprocedural administration of colchicine on markers of myocardial injury and inflammation in patients undergoing PCI.

The trial sought to identify the potential for colchicine—an anti-inflammatory drug which is primarily used in the treatment of gout—to reduce damage caused by opening up a blockage in the arteries of the heart, as well as the potential to reduce the risk of major adverse events following PCI. Properties of colchicine include inhibiting chemotaxis and activity in response to vascular injury, inhibiting inflammasome signalling and reducing neutrophil-platelet interaction and aggregation. Shah and colleagues hypothesised that an acute, pre-procedural oral administration of 1.8 mg of colchicine, administered one to two hours prior to procedure, would reduce biomarker evidence of PCI-related inflammation and myocardial injury when compared with placebo.

A total of 1,453 patients with suspected ischaemic heart disease or acute coronary syndromes referred for clinically-indicated coronary angiography with possible PCI, were eligible for inclusion in the study. After exclusion criteria were applied, 714 patients were enrolled, with 366 randomised to the colchicine group and 348 to the placebo group. Of those in the colchicine group, 206 underwent PCI, alongside 194 in the placebo group.

The primary outcome assessed through the trial was PCI-related myocardial injury, based on levels of troponin, with key secondary outcomes including mortality, non-fatal myocardial infarction or target vessel revascularization at 30 days. The study group found a 57.3% rate of PCI-related myocardial injury in the colchicine group (118), compared to 64.2% in the placebo group (122) (p=0.19). In terms of secondary outcomes, the study group noted an 11.7% (24) rate of 30-day major adverse cardiovascular events in the colchicine group, and 12.9% (25) in the placebo group (p=0.82).

COLCHICINE-PCI also assessed inflammatory biomarkers, looking at the difference in the change in plasma IL-6 and hsCRP concentrations from baseline to one hour, 6 hours, and 24 hours post-PCI. Shah and colleagues found that while the acute, pre-procedural dose of colchicine did not reduce PCI-related myocardial injury or MACE at 30 days, a PCI-related increase in IL-6 and hsCRP concentration was significantly attenuated at 24 hours post-PCI. Consequently, an earlier start to pre-procedural colchicine regimen warrants further investigation. COLCHICINE-PCI is the first study to demonstrate that an oral load of colchicine prevents a rise of inflammatory biomarkers in acute injury, according to Shah and colleagues.

Shah acknowledged that the trial was limited by a majority male population, while observations were limited to the selected acute pre-procedural dosing regimen, and the short-term time points for biomarkers of myocardial injury and inflammation.

Subodh Verma (University of Toronto; Toronto; Canada), who provided the discussant review for COLCHICINE-PCI, described the trial as a ‘well conducted and executed study’ and commented that more studies are needed targeting patients with residual inflammatory risk.

Funding for the COLCHICINE-PCI study came from the VA Career Development Award and the American Heart Association Clinical Research Mentored grant.

Source CardiovascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: Preprocedural COLCHICINE-PCI finds a lowering of inflammation, but no reduction in myocardial injury

Chia sẽ qua google bài: Preprocedural COLCHICINE-PCI finds a lowering of inflammation, but no reduction in myocardial injury

Chia sẽ qua twitter bài: Preprocedural COLCHICINE-PCI finds a lowering of inflammation, but no reduction in myocardial injury

Chia sẽ qua MySpace bài: Preprocedural COLCHICINE-PCI finds a lowering of inflammation, but no reduction in myocardial injury

Chia sẽ qua LinkedIn bài: Preprocedural COLCHICINE-PCI finds a lowering of inflammation, but no reduction in myocardial injury

Chia sẽ qua stumbleupon bài: Preprocedural COLCHICINE-PCI finds a lowering of inflammation, but no reduction in myocardial injury

Chia sẽ qua icio bài: Preprocedural COLCHICINE-PCI finds a lowering of inflammation, but no reduction in myocardial injury

Chia sẽ qua digg bài: Preprocedural COLCHICINE-PCI finds a lowering of inflammation, but no reduction in myocardial injury

Chia sẽ qua yahoo bài: Preprocedural COLCHICINE-PCI finds a lowering of inflammation, but no reduction in myocardial injury

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.